Validating a breast cancer score in Spanish women: The MCC-Spain study

Dierssen Sotos, Trinidad
Gómez Acebo, Inés
Fernández-Navarro, Pablo
Altzibar, Jone-Miren
González-Donquiles, Carmen
Ardanaz, Eva
Bustamante, Mariona
Alonso Molero, Jessica
Vidal, Carmen
Bayo Calero, Juan
García Tardón, Adonina
Salas Trejo, Dolores
Moreno, Victor
Rodriguez Cundin, Paz
Castaño-Vinyals, Gemma
Ederra, María
Vilorio Marqués, Laura
Amiano, Pilar
Pérez-Gómez, Beatriz
Aragonés, Nuria
Kogevinas, Manolis
Pollán, Marina
Llorca, Javier
A breast-risk score, published in 2016, was developed in white-American women using 92 genetic variants (GRS92), modifiable and non-modifiable risk factors. With the aim of validating the score in the Spanish population, 1,732 breast cancer cases and 1,910 controls were studied. The GRS92, modifiable and non-modifiable risk factor scores were estimated via logistic regression. SNPs without available genotyping were simulated as in the aforementioned 2016 study. The full model score was obtained by combining GRS92, modifiable and non-modifiable risk factor scores. Score performances were tested via the area under the ROC curve (AUROC), net reclassification index (NRI) and integrated discrimination improvement (IDI). Compared with non-modifiable and modifiable factor scores, GRS92 had higher discrimination power (AUROC: 0.6195, 0.5885 and 0.5214, respectively). Adding the non-modifiable factor score to GRS92 improved patient classification by 23.6% (NRI = 0.236), while the modifiable factor score only improved it by 7.2%. The full model AUROC reached 0.6244. A simulation study showed the ability of the full model for identifying women at high risk for breast cancer. In conclusion, a model combining genetic and risk factors can be used for stratifying women by their breast cancer risk, which can be applied to individualizing genetic counseling and screening recommendations ​
This document is licensed under a Creative Commons:Attribution (by) Creative Commons by4.0